Disease-A-Month
Volume 52, Issue 10 , Pages 367-384 , October 2006

Migraine Headaches: A Historical Prospective, a Glimpse into the Future, and Migraine Epidemiology

  • Jeff Unger, MD

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Dr. Jeff Unger, Chino Medical Group Headache Intervention Center, 5475 Walnut, Chino, CA 91710

References 

  1. Edmeads J. The treatment of headache: a historical perspective. In:  Gallagher RM editors. Therapy for headache. New York: Marcel Dekker; 1990;p. 1–8
  2. Alvarez WC. Was there sick headache in 3000 BC?. Gastroenterology. 1945;5:524
  3. Lance JW. Mechanisms and management of headache. 4th edition. London: Butterworth Scientific; 1982;
  4. Rosner F. Headache in the writings of Moses, Maimonides and other Hebrew sages. Headache. 1993;33:315–319
  5. Silberstein SD, Lipton RB, Goadsby PJ. Historical introduction. In: Headache in clinical practice. London: Martin Dunitz; 1998;p. 2
  6. Critchley M. Migraine: from Cappodocia to Queen Square. In:  Smith R editors. Background to migraine. London: Heinemann; 1967;p. 28–38
  7. Pearce JMS. The headaches of Thomas Jefferson. Cephalalgia. 2003;23:472–473
  8. Chestnutt M. Mary Chestnutt’s Civil War. New Haven: Yale University Press; 1981;
  9. King S. Firestarter. New York: Viking Press; 1980;
  10. Graham JR, Wolff HG. Mechanisms of migraine headache and action of ergotamine tartrate. Arch Neurol Psychiatry. 1938;39:737–763
  11. Silberstein SD. The pharmacology of ergotamine and dihydroergotamine. Headache. 1997;37:S15–S25
  12. Welch KMA, Nagesh V, Aurora SK, et al. Periaqueductal gray matter dysfunction in migraine: cause or the burden of illness?. Headache. 2001;41:629–637
  13. Anthony M, Hinterberger H, Lance JW. Plasma serotonin in migraine and stress. Arch Neurol. 1967;16:544–552
  14. Humphrey PPA, Perren MJ, Feniuk W, et al. The pharmacology of the novel 5-HT1-like receptor agonist GR43175. Cephalalgia. 1989;9(Suppl 9):23–33
  15. Humphrey PPA, Feniuk W, Marriott AS, et al. Preclinical studies on the anti-migraine drug, sumatriptan. Eur J Neurol. 1991;31:282–290
  16. Perrin VL, Farkkila M, Goasguen J, et al. Overview of initial clinical studies with intravenous and oral GR43175 in acute migraine. Cephalalgia. 1989;9:63–72
  17. Cady RK, Wendt JK, Kirchner JR, et al. Treatment of acute migraine with subcutaneous sumatriptan. JAMA. 1991;265:2831–2835
  18. Unger J, Cady RK, Farmer-Cady K. Migraine headaches, part 2: treatment options. The Female Patient. 2003;28:1–8
  19. Goadsby PJ, Lipton RB, Ferrari MD. Migraine: current understanding and treatment. N Engl J Med. 2002;346:257–270
  20. Ferrari MD, Saxena PR. Clinical and experimental effects of sumatriptan in humans. Trends Pharmacol Sci. 1993;14:129–133
  21. Goadsby PJ. The pharmacology of headache. Prog Neurobiol. 2000;62:509–525
  22. Mitsikostas DD, Sanches del Rio M, Moskowits MA, et al. Both 5-HT1B and 5 HT1F receptors modulate c-fos expression within rat trigeminal nucleus caudalis. Eur J Pharmacol. 1999;369:271–277
  23. Goadsby PJ, Edvinsson L. The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes see in humans and cats. Ann Neurol. 1993;33:48–56
  24. Storer RJ, Akerman S, Goadsby PJ. Calcitonin gene-related peptide (CGRP) receptor antagonist modulates nociceptive trigeminovascular transmission in the cat. Br J Pharmacol. 2004;142:1171–1181
  25. Edvinsson L. Blockade of CGRP receptors in the intracranial vasculature: a new target in the treatment of headache. Cephalalgia. 2004;24:611–622
  26. Tvedskov JF, Iversen HK, Olesen J. A double-blind study of SB-220453 (Tonerbasat) in the glyceryltrinitrate (GTN) model of migraine. Cephalgia. 2004;24:875–882
  27. Villalon CM, Centurion D, Valdivia LF, et al. An introduction to migraine: from ancient treatment to functional pharmacology and antimigraine therapy. Proc West Pharmacol Soc. 2002;45:199–210
  28. Den Boer MO, Heiligers JP, Saxena PR. Carotid vascular effects of ergotamine and dihydroergotamine in the pig: no exclusive mediation via 5-HT 1-like receptors. Br J Pharmacol. 1998;123:1561–1570
  29. Kapoor K, Willems W, Maassen VanDenBrink A, et al. Assessment of anti-migraine potential of a novel alpha-adrenoceptor agonist S19014: effects on porcine carotid and regional haemodynamics and human coronary artery. Cephalagia. 2004;24:425–438
  30. Breslau N, Chilcoat H, Andreski P. Further evidence on the link between migraine and neuroticism. Neurology. 1996;47:663–667
  31. Rozen TD, Swanson JW, Stang PE, et al. Incidence of medically recognized migraine: a 1989–1990 study in Olmsted County, Minnesota. Headache. 2000;40:216–223
  32. Cady RK, Weidman E, Unger J, et al. Pediatric migraine. Available at: www.primarycarenet.org/cme/CME11.CFM. Accessed February 11, 2005.
  33. Scherer AI, Stewart WF, Lipton RB. 1999. Migaine and headache: a meta-analytic approach. In:  Crombie I editors. Epidemiology of pain. Seattle (WA): IASP Press; 1999;p. 159–170
  34. Lavados PM, Tehnamm E. Epidemiology of migraine headache in Santiago, Chile: a prevalence study. Cephalalgia. 1997;17:770–777
  35. Rasmussen BK, Olesen J. Epidemiology of migraine and tension-type headache. Curr Opin Neurol. 1994;7:264–271
  36. Rasmussen BK. Epidemiology of migraine. Biomed Pharmacother. 1995;49:452–455
  37. Lipton RB, Silberstein SD, Stewart WF. An update on the epidemiology of migraine. Headache. 1994;34:319–328
  38. Sakai F, Igarashi H. Prevalence of migraine in Japan: a nationwide survey. Cephalalgia. 1997;17:15–22
  39. Sheffield RE. Migraine prevalence: a literature review. Headache. 1998;38:595–601
  40. Sheftell FD, Tepper SJ. New paradigms in the recognition and acute treatment of migraine. Headache. 2002;42:58–69
  41. Lipton RB, Stewart WF, Reed M, et al. Migraine’s impact today burden of illness, patterns of care. Postgrad Med. 2001;109:38–45
  42. Stewart WF, Lipton RB, Liberman J. Variation in migraine prevalence by race. Neurology 1996a;16:231–8.
  43. Headache disorders and public health. Geneva, Switzerland: World Health Organization; 2000;
  44. Clarke CE, MacMillan L, Sondhi S, et al. Economic and social impact of migraine. Q J Med. 1996;89:77–84
  45. Stewart WF, Lipton RB, Celentano DD, et al. Prevalence of migraine headache in the United States: relation to age, income, race and other sociodemographic factors. JAMA. 1992;267:64–69
  46. Vinson DR. Treatment patterns of isolated benign headache in US emergency departments. Ann Emerg Med. 2002;39:215–222
  47. Stang PE, Crown WH, Biz R, et al. The family impact and costs of migraine. Am J Manag Care. 2004;10:313–320
  48. Edmeads J, Mackell JA. The economic impact of migraine: an analysis of direct and indirect costs. Headache. 2002;42:501–509
  49. Hu XH, Markson LE, Lipton RB, et al. Burdon of migraine in the United States disability and economics costs. Arch Intern Med. 1999;159:813–818
  50. Osterhaus JT, Gutterman DL, Plachetka JR. Health care resource and lost labor: cost of migraine headache in the United States. Pharmacoeconomics. 1992;2:67–76
  51. Hu XH, Markson LE, Lipton RB, et al. Burden of migraine in the United States: disability and economic costs. Arch Intern Med. 1999;159:813–818
  52. Lipton RB, Stewart WF, von Korff M. Burden of migraine: societal costs and therapeutic opportunities. Neurology. 1997;48(Suppl 3):S4–S9
  53. Scher A, Stewart W, Libertman J, et al. Prevalence of frequent headache in a population sample. Headache. 1998;38:497–596
  54. Mitsikostas DD, Thomas AM. Comorbidity of headache and depressive disorders. Cephalalgia. 1999;19:211–217
  55. Pesa J, Lage MJ. The medical costs of migraine and comorbid anxiety and depression. Headache. 2004;44:562–570
  56. Evers S, Suhr B, Bauer B, et al. A retrospective long-term analysis of the epidemiology and features of drug-induced headache. J Neurol. 1999;246:802–809
  57. Silberstein SD, Silberstein JR. Chronic daily headache: long-term prognosis following inpatient treatment with repetitive IV DHE. Headache. 1992;32:439–445
  58. Unger J. The challenge of managing chronic pain in primary care: what critical historical clues are we missing. [editorial] The Female Patient. 2004;29:8–9
  59. Katsarava Z, Muessig M, Dzagnidze A, et al. Medication overuse headache: rates and predictors for relapse in a 4-year prospective study. Cephalalgia. 2005;25:12–15
  60. Fritsche G, Eberl A, Katsarava Z, et al. Drug-induced headache: long-term follow-up of withdrawal therapy and persistence of drug misuse. Eur Neurol. 2001;45:229–235
  61. Lipton RB, Diamond S, Reed M, et al. Migraine diagnosis and treatment: results from the American Migraine Study II. Headache. 2001;41:638–645

PII: S0011-5029(06)00085-X

doi: 10.1016/j.disamonth.2006.09.002

Disease-A-Month
Volume 52, Issue 10 , Pages 367-384 , October 2006

Article Tools

* Image Usage & Resolution